Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
2(18%)
Results Posted
120%(6 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_2
3
27%
Ph not_applicable
1
9%
Ph phase_1
5
45%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(5)
Terminated(3)
Other(1)

Detailed Status

Completed5
Terminated2
Recruiting1
unknown1
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 23 (30.0%)
Phase 31 (10.0%)
N/A1 (10.0%)

Trials by Status

recruiting19%
completed545%
unknown19%
active_not_recruiting19%
withdrawn19%
terminated218%

Recent Activity

2 active trials
Showing 5 of 11
active_not_recruitingphase_3

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT02306161
recruitingnot_applicable

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NCT04199026
completedphase_1

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NCT00788957
terminatedphase_2

Palbociclib + Ganitumab In Ewing Sarcoma

NCT04129151
completedphase_2

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

NCT00891930
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02306161Phase 3

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active Not Recruiting
NCT04199026Not Applicable

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting
NCT00788957Phase 1

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Completed
NCT04129151Phase 2

Palbociclib + Ganitumab In Ewing Sarcoma

Terminated
NCT00891930Phase 2

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed
NCT03041701Phase 1

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Terminated
NCT01327612Phase 2

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed
NCT03029481

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Unknown
NCT01473303Phase 1

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Withdrawn
NCT01298401Phase 1

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Completed
NCT00562380Phase 1

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Completed

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11